GlassScriptPhysician profile
Jose R Mole
NPI 1629092283
$4,431.99
in general payments reported to CMS, 2019-2025
27 companies · $39.62 in 2025
The $39.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $147 · 2021: $900 · 2022: $937 · 2023: $615 · 2024: $654 · 2025: $39.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $906.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $844.73 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $531.23 | 2019-2022 | |
| Abbvie INC. | $443.79 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $402.85 | 2021-2024 | |
| Glaxosmithkline, LLC. | $231.88 | 2019-2024 | Trelegy Ellipta |
| Ethicon INC. | $147.58 | 2022 | |
| Amgen INC. | $131.73 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.03 | 2019-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $102.66 | 2019-2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.35 | 2019 | |
| Pfizer INC. | $63.34 | 2019-2020 | |
| Astellas Pharma US INC | $63.05 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $51.37 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.06 | 2019-2022 | |
| Almatica Pharma LLC | $30.17 | 2021 | |
| Hologic Sales and Service, LLC | $26.31 | 2023 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Genentech USA, INC. | $23.18 | 2019 | |
| Nevro Corp. | $22.44 | 2019 | |
| Allergan, INC. | $20.96 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.74 | 2022 | |
| Averitas Pharma INC. | $19.99 | 2024 | Qutenza |
| Eisai INC. | $18.87 | 2022 | |
| Lundbeck LLC | $15.51 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2021 | |
| Merck Sharp & Dohme LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Mole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.